The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread

FEMS Microbiology Reviews

Volumn 41, Issue 1, 2017, Pages 34-48

  Woodrow, Charles J ^a   White, Nicholas J ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

ACT; Artemisinin; Kelch; Malaria; Resistance; Southeast Asia

Indexed keywords

ARTEMETHER; ARTEMISININ; ARTESUNATE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

AFRICA; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; CAMBODIA; CONSENSUS; DRUG EFFICACY; DRUG MONITORING; GENE MUTATION; GENOTYPE; HUMAN; INDIA; LONG TERM CARE; MALARIA CONTROL; MALARIA FALCIPARUM; PARASITE CLEARANCE; PHENOTYPE; REVIEW; THAILAND; DRUG EFFECTS; DRUG RESISTANCE; FORECASTING; GENETICS; MUTATION; PLASMODIUM FALCIPARUM; SOUTHEAST ASIA;

ANTIMALARIALS; ARTEMISININS; ASIA, SOUTHEASTERN; DRUG RESISTANCE; FORECASTING; HUMANS; MALARIA, FALCIPARUM; MUTATION; PLASMODIUM FALCIPARUM;

EID: 85013745617     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1093/femsre/fuw037     Document Type: Review

References (144)

1. Adjuik M, Babiker A, Garner P et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004;363: 9-17
2. Alin MH, Bjorkman A. Concentration and time dependency of artemisinin efficacy against Plasmodium falciparum in vitro. Am J Trop Med Hyg 1994;50:771-6
3. Alker AP, Lim P, Sem R et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 2007;76: 641-7
4. Amaratunga C, Lim P, Suon S et al. Dihydroartemisininpiperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016;16:357-65
5. Amaratunga C, Neal AT, Fairhurst RM. Flow cytometry-based analysis of artemisinin-resistant Plasmodium falciparum in the ring-stage survival assay. Antimicrob Agents Ch 2014;58:4938-40
6. Amaratunga C, Sreng S, Suon S et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012;12: 851-8
7. Anderson TJ, Nair S, Nkhoma S et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis 2010;201:1326-30
8. Ariey F, Witkowski B, Amaratunga C et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50-5
9. Ashley EA, Dhorda M, Fairhurst RM et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371:411-23
10. Bancone G, Chowwiwat N, Somsakchaicharoen R et al. Single low dose primaquine (0. 25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS One 2016;11:e0151898
11. Basco LK. Field Application of In Vitro Assays for the Sensitivity of Human Malaria Parasites to Antimalarial Drugs. Geneva: WHO, 2007
12. Bethell D, Se Y, Lon C et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One 2011;6:e19283
13. Bhatt S, Weiss DJ, Cameron E et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015;526:207-11
14. Boni MF, White NJ, Baird JK. The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies. PLoS Med 2016;13:e1001984
15. Borrmann S, Sasi P, Mwai L et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011;6:e26005
16. Boyden LM, Choi M, Choate KA et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012;482:98-102
17. Buffet PA, Milon G, Brousse V et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 2006;107:3745-52
18. Carrara VI, Lwin KM, Phyo AP et al. Malaria burden and artemisinin resistance in themobile andmigrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med 2013;10:e1001398
19. Carrara VI, Zwang J, Ashley EA et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 2009;4:e4551
20. Cheeseman IH, Miller BA, Nair S et al. A major genome region underlying artemisinin resistance in malaria. Science 2012;336:79-82
21. Chenet SM, Akinyi Okoth S, Huber CS et al. Independent emergence of the Plasmodium falciparum kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis 2016;213: 1472-5
22. Chotivanich K, Tripura R, Das D et al. Laboratory detection of artemisinin-resistant Plasmodium falciparum. Antimicrob Agents Ch 2014;58:3157-61
23. Chotivanich K, Udomsangpetch R, Dondorp A et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000;182: 629-33
24. Cobbold SA, Chua HH, Nijagal B et al. Metabolic dysregulation induced in Plasmodium falciparum by dihydroartemisinin and other front-line antimalarial drugs. J Infect Dis 2016;213:276-86
25. Curtis CF, Otoo LN. A simple model of the build-up of resistance to mixtures of anti-malarial drugs. T Roy Soc Trop Med H 1986;80:889-92
26. Das D, Tripura R, Phyo AP et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 2013;56:e48-58
27. David-Bosne S, Clausen MV, Poulsen H et al. Reappraising the effects of artemisinin on the ATPase activity of PfATP6 and SERCA1a E255L expressed in Xenopus laevis oocytes. Nat Struct Mol Biol 2016;23:1-2
28. Denis MB, Davis TM, Hewitt S et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002;35:1469-76
29. Denis MB, Tsuyuoka R, Lim P et al. Efficacy of artemetherlumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health 2006a;11:1800-7
30. Denis MB, Tsuyuoka R, Poravuth Y et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2006b;11:1360-6
31. Dogovski C, Xie SC, Burgio G et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol 2015;13:e1002132
32. Dondorp A, Nosten F, Stepniewska K et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005;366:717-25
33. Dondorp AM, Fanello CI, Hendriksen IC et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010;376:1647-57
34. Dondorp AM, Nosten F, Yi P et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67
35. Duru V, Khim N, Leang R et al. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations. BMC Med 2015;13:305
36. Fairhurst RM. Understanding artemisinin-resistant malaria: what a difference a year makes. Curr Opin Infect Dis 2015;28:417-25
37. Fairhurst RM, Nayyar GM, Breman JG et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg 2012;87:231-41
38. Flegg JA, Guerin PJ, Nosten F et al. Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malaria J 2013;12:411
39. Flegg JA, Guerin PJ, White NJ et al. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malaria J 2011;10:339
40. Gardner KB, Sinha I, Bustamante LY et al. Protein-based signatures of functional evolution in Plasmodium falciparum. BMC Evol Biol 2011;11:257
41. Geary TG, Divo AA, Jensen JB. Stage specific actions of antimalarial drugs on Plasmodium falciparum in culture. Am J Trop Med Hyg 1989;40:240-4
42. Ghorbal M, Gorman M, Macpherson CR et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol 2014;32: 819-21
43. Hayes JD, McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 2006;21:732-4
44. Hien TT, Thuy-Nhien NT, Phu NH et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malaria J 2012;11:355
45. Hott A, Casandra D, Sparks KN, Morton LC et al. Artemisininresistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob Agents Ch 2015;59:3156-67
46. Huang F, Takala-Harrison S, Jacob CG et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis 2015;212:1629-35
47. Imwong M, Jindakhad T, Kunasol C et al. An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. Sci Rep 2015;5:17412
48. Ismail HM, Barton V, Phanchana M et al. Artemisinin activitybased probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. P Natl Acad Sci USA 2016;113:2080-5
49. Janssens B, van HerpM, Goubert L et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisininpiperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2007;12: 251-9
50. Kamau E, Campino S, Amenga-Etego L et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2015;211:1352-5
51. Khin HS, Chen I, White C et al. Availability and quality of antimalarials among private sector outlets in Myanmar in 2012: results from a large, community-based, cross-sectional survey before a large-scale intervention. Malaria J 2015;14:269
52. Klonis N, Crespo-Ortiz MP, Bottova I et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. P Natl Acad Sci USA 2011;108: 11405-10
53. Klonis N, Xie SC, McCaw JM et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. P Natl Acad Sci USA 2013;110:5157-62
54. Kyaw MP, Nyunt MH, Chit K et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 2013;8:e57689
55. Leang R, Barrette A, Bouth DM et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Ch 2013;57: 818-26
56. Leang R, Canavati SE, Khim N et al. Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Ch 2016;60:3884-90
57. Leang R, Taylor WR, Bouth DM et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine inWestern Cambodia: dihydroartemisininpiperaquine open-labelmulticenter clinical assessment. Antimicrob Agents Ch 2015;59:4719-26
58. Li GQ, Arnold K, Guo XB et al. Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. Lancet 1984;2:1360-1
59. Lon C, Manning JE, Vanachayangkul P et al. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One 2014;9:e93138
60. Maiga-Ascofare O, May J. Is the A578S single-nucleotide polymorphism in K13-propeller a marker of emerging resistance to artemisinin among plasmodium falciparum in Africa? J Infect Dis 2016;213:165-6
61. MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. Elife 2016;5
62. Maude RJ, Pontavornpinyo W, Saralamba S et al. The last man standing is the most resistant: eliminating artemisininresistant malaria in Cambodia. Malaria J 2009;8:31
63. Mbengue A, Bhattacharjee S, Pandharkar T et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 2015;520:683-7
64. Menard D, Khim N, Beghain J et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med 2016;374:2453-64
65. Menard S, Ben Haddou T, Ramadani AP et al. Induction of multidrug tolerance in Plasmodium falciparum by extended artemisinin pressure. Emerg Infect Dis 2015;21: 1733-41
66. Miao M, Wang Z, Yang Z et al. Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion. PLoS One 2013;8:e59192
67. Miotto O, Almagro-Garcia J, ManskeMet al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 2013;45:648-55
68. Miotto O, Amato R, Ashley EA et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 2015;47:226-34
69. Mok S, Ashley EA, Ferreira PE et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science 2015;347: 431-5
70. Na-Bangchang K, Ruengweerayut R, Mahamad P et al. Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in amulti-drug resistance area along the Thai-Myanmar border. Malar J 2010;9:273
71. Nayyar GM, Breman JG, Newton PN et al. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012;12:488-96
72. Newton P, Proux S, Green M et al. Fake artesunate in southeast Asia. Lancet 2001;357:1948-50
73. Nguyen TD, Olliaro P, Dondorp AM et al. Optimum populationlevel use of artemisinin combination therapies: a modelling study. Lancet Glob Health 2015;3:e758-66
74. Noedl H, Se Y, Schaecher K et al. Evidence of artemisininresistant malaria in western Cambodia. N Engl J Med 2008;359:2619-20
75. Noedl H, Se Y, Sriwichai S et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 2010;51:e82-89
76. Nosten F, Luxemburger C, ter Kuile FO et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994;170:971-7
77. Nosten F, van Vugt M, Price R et al. Effects of artesunatemefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000;356:297-302
78. Nyunt MH, Hlaing T, Oo HW et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the K13 propeller, and a multidrug-resistance gene in the Eastern and Western Border Areas of Myanmar. Clin Infect Dis 2015;60:1208-15
79. Ouattara A, Kone A, Adams M et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. Am J Trop Med Hyg 2015;92:1202-6
80. Padmanabhan B, Tong KI, Ohta T et al. Structural basis for defects of Keap1 activity provoked by its pointmutations in lung cancer. Mol Cell 2006;21:689-700
81. Peak CM, Thuan PD, Britton A et al. Measuring the association between artemisinin-based case management and malaria incidence in southern Vietnam, 1991-2010. Am J Trop Med Hyg 2015;92:811-7
82. Pennings PS, Hermisson J. Soft sweeps III: the signature of positive selection from recurrent mutation. PLoS Genet 2006;2:e186
83. Phyo AP, Ashley EA, Anderson TJ et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors. Clin Infect Dis 2016a
84. Phyo AP, Jittamala P, Nosten FH et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis 2016b;16:61-9
85. Phyo AP, Nkhoma S, Stepniewska K et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379:1960-6
86. Price R, Luxemburger C, van Vugt M et al. Artesunate and mefloquine in the treatment of uncomplicated multidrugresistant hyperparasitaemic falciparum malaria. T Roy Soc Trop Med H 1998a;92:207-11
87. Price R, van Vugt M, Nosten F et al. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am J Trop Med Hyg 1998b;59:883-8
88. Price RN, Uhlemann AC, Brockman A et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004;364:438-47
89. Putaporntip C, Kuamsab N, Kosuwin R et al. Natural selection of K13 mutants of Plasmodium falciparum in response to artemisinin combination therapies in Thailand. Clin Microbiol Infect 2016;22:285, e281-8
90. RogersWO, Sem R, Tero T et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malaria J 2009; 8:10
91. Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 2010;10:51-9
92. Roper C, Alifrangis M, Ariey F et al. Molecular surveillance for artemisinin resistance in Africa. Lancet Infect Dis 2014;14:668-70
93. Roper C, Pearce R, Nair S et al. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004;305:1124
94. Rottmann M, McNamara C, Yeung BK et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010;329:1175-80
95. Rueangweerayut R, Phyo AP, Uthaisin C et al. Pyronaridineartesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012;366:1298-309
96. Saralamba S, Pan-Ngum W, Maude RJ et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. P Natl Acad Sci USA 2011;108:397-402
97. Satimai W, Sudathip P, Vijaykadga S et al. Artemisinin resistance containment project in Thailand. II: Responses to mefloquine-artesunate combination therapy among falciparum malaria patients in provinces bordering Cambodia. Malaria J 2012;11:300
98. Saunders DL, Vanachayangkul P, Lon C. Dihydroartemisininpiperaquine failure in Cambodia. NEngl J Med 2014;371:484-5
99. Shute PG, Maryon M. A contribution to the problem of strains of human plasmodium. Riv Malariol 1954;33:1-21
100. Simpson JA, McCaw J, Fowkes FJ. Parasite strain, host immunity, and circulating blood cells with dead parasites: why predicting malaria parasite clearance is not a simple task. Antimicrob Agents Ch 2016;60:1172
101. Skinner TS, Manning LS, Johnston WA et al. In vitro stagespecific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasitol 1996;26:519-25
102. Smithuis F, Kyaw MK, Phe O et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an openlabel randomised trial. Lancet Infect Dis 2010;10:673-81
103. Spring MD, Lin JT, Manning JE et al. Dihydroartemisininpiperaquine failure associated with a triplemutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis 2015;15:683-91
104. St Laurent B, Miller B, Burton TA et al. Artemisinin-resistant Plasmodium falciparum clinical isolates can infect diverse mosquito vectors of Southeast Asia and Africa. Nat Commun 2015;6:8614
105. Stepniewska K, Ashley E, Lee SJ et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis 2010;201:570-9
106. Straimer J, Gnadig NF, Witkowski B et al. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015;347:428-31
107. Takala-Harrison S, Clark TG, Jacob CG et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. P Natl Acad Sci USA 2013;110:240-5
108. Takala-Harrison S, Jacob CG, Arze C et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015;211: 670-9
109. Talundzic E, Okoth SA, Congpuong K et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog 2015;11:e1004789
110. Taylor SM, Parobek CM, DeConti DK et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015;211:680-8
111. ter Kuile F, White NJ, Holloway P et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993;76:85-95
112. Teuscher F, Gatton ML, Chen N et al. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 2010;202:1362-8
113. Thriemer K, Hong NV, Rosanas-Urgell A et al. Delayed parasite clearance after treatment with dihydroartemisininpiperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Ch 2014;58:7049-55
114. Tilley L, Straimer J, Gnadig NF et al. Artemisinin action and resistance in Plasmodium falciparum. Trends Parasitol 2016
115. Toure OA, Rulisa S, Anvikar AR et al. Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study. Malaria J 2015;14:469
116. Toure OA, Valecha N, Tshefu AK et al. A Phase 3, Double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa. Clin Infect Dis 2016;62:964-71
117. Tun KM, Imwong M, Lwin KM et al. Spread of artemisininresistant Plasmodium falciparum in Myanmar: a crosssectional survey of the K13 molecular marker. Lancet Infect Dis 2015;15:415-21
118. Tun KM, Jeeyapant A, Imwong M et al. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria J 2016;15:185
119. Tyner SD, Lon C, Se Y et al. Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay. Malaria J 2012;11:198
120. Venkatesan M, Gadalla NB, Stepniewska K et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter andmultidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014;91:833-43
121. Vijaykadga S, Rojanawatsirivej C, Cholpol S et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunatemefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health 2006;11:211-9
122. Wang J, Zhang CJ, Chia WN et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun 2015a;6:10111
123. Wang Z, Wang Y, Cabrera M et al. Artemisinin resistance at the China-Myanmar border and association with mutations in the K13 propeller gene. Antimicrob Agents Ch 2015b;59: 6952-9
124. Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov 2015;14: 424-42
125. White LJ, Flegg JA, Phyo AP et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med 2015;12:e1001823
126. White NJ. Antimalarial drug resistance. J Clin Invest 2004;113:1084-92
127. White NJ, Pongtavornpinyo W, Maude RJ et al. Hyperparasitaemia and low dosing are an important source of antimalarial drug resistance. Malaria J 2009;8:253
128. White NJ, Pukrittayakamee S, Phyo AP et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 2014;371:403-10
129. Win AA, Imwong M, Kyaw MP et al. K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malaria J 2016;15:110
130. Winzeler EA, Manary MJ. Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol 2014;15:544
131. Witkowski B, Amaratunga C, Khim N et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 2013a;13: 1043-9
132. Witkowski B, Khim N, Chim P et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Ch 2013b;57:914-23
133. Witkowski B, Lelievre J, Barragan MJ et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Ch 2010;54: 1872-7
134. World Health Organization. Chemotherapy of Malaria. Report of a WHO scientific group. (WHO Technical Report Series, No. 375). Geneva, Switzerland: World Health Organization, 1967
135. World Health Organization. Status Report on Artemisinin Resistance: September 2015. Geneva, Switzerland:World Health Organization, 2015
136. WWARN ACT Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med 2015;13:212
137. WWARN Artemether-Lumefantrine Dose Impact Study Group. The effect of dose on the antimalarial efficacy of artemetherlumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis 2015;15:692-702
138. WWARN Artesunate-Amodiaquine Study Group. The effect of dosing strategies on the therapeutic efficacy of artesunateamodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med 2015;13:66
139. WWARN DHA-Piperaquine Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisininpiperaquine: a pooled analysis of individual patient data. PLoS Med 2013;10:e1001564; discussion e1001564
140. WWARN Lumefantrine PK-PD Study Group. Artemetherlumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med 2015;13:227
141. WWARN Parasite Clearance Study Group. Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria J 2015;14:359
142. Xie SC, Dogovski C, Hanssen E et al. Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins. J Cell Sci 2016;129:406-16
143. Ye R, Hu D, Zhang Y et al. Distinctive origin of artemisininresistant Plasmodium falciparum on the China-Myanmar border. Sci Rep 2016;6:20100
144. Yeung S, Van Damme W, Socheat D et al. Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J 2008;7:96